# A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

> **NCT07165015** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 31 (actual)

## Conditions studied

- Renal Impairment
- Healthy
- Renal Insufficiency
- End Stage Renal Disease (ESRD)

## Interventions

- **DRUG:** LY3537031

## Key facts

- **NCT ID:** NCT07165015
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-18
- **Primary completion:** 2026-04-16
- **Final completion:** 2026-04-16
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07165015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07165015, "A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07165015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*